Oct. 1, 2015 1:19 PM ET |
Roche’s (OTCQX:RHHBY) boast on Monday to have in ocrelizumab the first project to show efficacy in a large phase III trial for primary progressive multiple sclerosis is quite a claim, and draws attention to this relatively rare but tricky form of the neurodegenerative disease.
The group might well celebrate: while the relapsing-remitting MS space is crowded, ocrelizumab is one of just a handful of projects in development for the primary progressive form (see table below). However, if Roche has stumbled on a new mechanistic insight this also raises questions that academics and biotechs alike will ask about competing CD20-targeting projects.
Continue learning of this HOPEFUL MS therapy